Ponatinib Linked With Better Outcomes Than Imatinib in Philadelphia Chromosome-Positive ALL
The phase 3 PhALLCON trial showed a trend toward improved EFS in patients with Ph+ newly diagnosed ALL when treated with ponatinib compared with imatinib.
The phase 3 PhALLCON trial showed a trend toward improved EFS in patients with Ph+ newly diagnosed ALL when treated with ponatinib compared with imatinib.
Researchers sought to determine whether JZP458 could maintain adequate nadir serum asparaginase activity in patients with ALL/LBL.
Living along the Texas-Mexico border is associated with worse survival in children diagnosed with acute lymphoblastic leukemia.
Reinfusion with the CAR T-cell therapy tisagenlecleucel does not produce durable remissions in children and AYAs with B-ALL, a study suggests.
Researchers sought to determine whether OS rates with CAR-T therapy were linked to household poverty and neighborhood opportunity for patients with ALL.
Researchers sought to determine if there is a link between congenital cytomegalovirus infection and risk of hyperdiploid ALL in pediatric patients.
Researchers sought to address the variability in definitions for key outcomes in trials involving pediatric ALL.
Researchers sought to determine whether race, ethnicity, or BMI would have an impact on CAR-T therapy in patients with B-ALL.
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
Blinatumomab-based consolidation is a new standard of care for ALL patients with MRD negativity after induction and intensification, researchers say.